• 1
    Cunningham WE, Markson LE, Andersen RM, et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States. HCSUS Consortium. HIV Cost and Services Utilization. J Acquir Immune Defic Syndr. 2000; 25: 115123.
  • 2
    Palella FJ Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338: 853860.
  • 3
    Cote TR, Biggar RJ, Rosenberg PS, et al. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. Int J Cancer. 1997; 73: 645650.
  • 4
    California Cancer Registry Data Standard and Quality Control Unit. Cancer reporting in California: abstracting and coding procedures for hospitals. California Cancer Reporting System Standards. Sacramento: California Cancer Registry, 2003.
  • 5
    Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992; 41: RR17.
  • 6
    PercyC, Van HoltenV, MuirC, editors. International classification of diseases for oncology, 2nd ed. Geneva: World Health Organization, 1990.
  • 7
    Anton-Culver H, Trejo R, Taylor TH, et al. Cancer incidence and mortality in San Diego County, 1996–2000. Irvine: Cancer Surveillance Program of Orange County/San Diego Imperial Organization for Cancer Control, Epidemiology Division, Department of Medicine, University of California–Irvine, 2003.
  • 8
    County of San Diego Health and Human Services Agency. County of San Diego HIV/AIDS Epidemiology Report 2004. San Diego: County of San Diego Health and Human Services Agency, 2004.
  • 9
    Esteve J, Benhamou E, Raymond L. Descriptive epidemiology. In: BreslowNE, DayNE, editors. Statistical methods in cancer research. Lyon: International Agency for Research on Cancer, 1994: 52, 6364.
  • 10
    Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol. 2001; 19: 21712178.
  • 11
    Straus DJ, Huang J, Testa MA, Levine AM, Kaplan LD, National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trial Group Protocol 142—low-dose vs. standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 1998; 16: 36013606.
  • 12
    Wilde JT, Lee CA, Darby SC, et al. The incidence of lymphoma in the UK haemophilia population between 1978 and 1999. AIDS. 2002; 16: 18031807.
  • 13
    Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood. 2001; 98: 23392344.
  • 14
    Grulich AE, Li Y, McDonald AM, Correll PK, Law MG, Kaldor JM. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. AIDS. 2001; 15: 629633.
  • 15
    Clarke CA. Changing incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma among young men in San Francisco. AIDS. 2001; 15: 19131915.
  • 16
    International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000; 92: 18231830.
  • 17
    Bhaskaran K, Brettle R, Porter K, Walker AS; CASCADE Collaboration. Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion: incidence and predictors. AIDS. 2004; 18: 673681.
  • 18
    Stebbing J, Gazzard B, Mandalia S, et al. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma. J Clin Oncol. 2004; 22: 21772183.
  • 19
    Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood. 2001; 98: 34063412.
  • 20
    Jones JL, Hanson DL, Dworkin MS, Ward JW, Jaffe HW, and the Adult/Adolescent Spectrum of HIV Disease Project Group. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. J Acquir Immune Defic Syndr. 1999; 21: S11S17.
  • 21
    Hoffmann C, Tabrizian S, Wolf E, et al. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS. 2001; 15: 21192127.
  • 22
    Newell ME, Hoy JF, Cooper SG, et al. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer. 2004: 100: 26272636.
  • 23
    Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS. 2003; 17: 17871793.
  • 24
    Vaccher E, Spina M, Talamini R, et al. Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy. Clin Infect Dis. 2003; 37: 15561564.
  • 25
    Hoffmann C, Wolf E, Fatkenheuer G, et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS. 2003; 17: 15211529.
  • 26
    Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS. 2001; 15: 14831491.
  • 27
    Gerard L, Galicier L, Maillard A, et al. Systemic non-Hodgkin's lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival. J Acquir Immune Defic Syndr. 2002; 30: 478484.
  • 28
    Rossi G, Donisi A, Casari S, Re A, Cadeo G, Carosi G. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma. Cancer. 1999; 86: 23912397.
  • 29
    Thiessard F, Morlat P, Marimoutou C, et al. Prognostic factors after non-Hodgkin's lymphoma in patients infected with human immunodeficiency virus, Aquitaine Cohort, France, 1986–1997. Cancer. 2000; 88: 16961702.
  • 30
    Carbone A. Emerging pathways in the development of AIDS-related lymphomas. Lancet Oncol. 2003; 4: 2229.
  • 31
    Levine AM, Seneviratne L, Espina BM, et al. Evolving characteristics of AIDS-related lymphoma. Blood. 2000; 96: 40844090.
  • 32
    Little RF. AIDS-related non-Hodgkin's lymphoma: etiology, epidemiology, and impact of highly active antiretroviral therapy. Leuk Lymphoma. 2003; 44: S63S68.
  • 33
    Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003; 101: 46534659.
  • 34
    Deloose ST, Smit LA, Pals FT, Kersten MJ, van Noesel CJ, Pals ST. High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma. Leukemia. 2005; 19: 851855.
  • 35
    Clarke CA, Glaser SL, Dorfman RF, Bracci PM, Eberle E, Holly EA. Expert review of non-Hodgkin's lymphoma in a population-based cancer registry: reliability of diagnosis and subtype classifications. Cancer Epidemiol Biomarkers Prev. 2004; 13: 138143.
  • 36
    Levine AM, Sullivan-Halley J, Pike MC, et al. Human immunodeficiency virus-related survival: prognostic factors predictive of survival. Cancer. 1991; 68: 24662472.
  • 37
    Cote TR, O'Brien TR, Ward JW, Wilson SE, Blattner WA, and the National AIDS/Cancer Match Study Group. AIDS and cancer registry linkage: measurement and enhancement of registry completeness. Prev Med. 1995; 24: 375377.
  • 38
    Clarke CA, Glaser SL. Population-based surveillance of HIV-associated cancers: utility of cancer registry data. J Acquir Immune Defic Syndr. 2004; 36: 10831091.
  • 39
    Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994–1998, the EuroSIDA Study. Lancet. 2000; 356: 291296.